LIVIVO - Search results -

Search results

Result 1 - 10 of total 125

Search options

Book: Advances in cancer biomarkers

Scatena, Roberto

from biochemistry to clinic for a critical revision

(Advances in experimental medicine and biology ; volume 867)

2015

Abstract: At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows ... ...

Author's details	Roberto Scatena editor
Series title	Advances in experimental medicine and biology ; volume 867
Collection
Abstract	"At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and "polluted" knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation"--Back cover
Keywords	Biomarkers, Tumor / analysis ; Neoplasms / diagnosis ; Early Detection of Cancer ; Neoplastic Processes
Subject code	616.9940072
Language	English
Size	ix, 372 Seiten, Illustrationen, Diagramme, 27 cm
Publisher	Springer
Publishing place	Dordrecht
Publishing country	Netherlands
Document type	Book
HBZ-ID	HT018891093
ISBN	978-94-017-7214-3 ; 978-94-017-7215-0 ; 94-017-7214-2 ; 94-017-7215-0
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 3192 -867-	not available for loan	Zeitschriften-Lesesaal

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Advances in cancer stem cell biology

Scatena, Roberto / Mordente, Alvaro / Giardina, Bruno

2012

Author's details	Roberto Scatena ; Alvaro Mordente ; Bruno Giardina
Language	English
Size	XII, 343 S. : Ill., graph. Darst., 24 cm
Publisher	Springer
Publishing place	New York u.a.
Publishing country	United States
Document type	Book
HBZ-ID	HT017035403
ISBN	978-1-4614-0808-6 ; 1-4614-0808-3 ; 9781461408093 ; 1461408091
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2011 A 4812	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Advances in mitochondrial medicine

Scatena, Roberto / Bottoni, Patrizia / Giardina, Bruno

(Advances in experimental medicine and biology ; 942)

2012

Author's details	Roberto Scatena ; Patrizia Bottoni ; Bruno Giardina ed
Series title	Advances in experimental medicine and biology ; 942
Collection
Language	English
Size	XII, 461 S. : Ill., graph. Darst.
Publisher	Springer
Publishing place	Dordrecht u.a.
Publishing country	Netherlands
Document type	Book
HBZ-ID	HT017183985
ISBN	978-94-007-2868-4 ; 94-007-2868-9 ; 9789400728691 ; 9400728697
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 3192 -942-	not available for loan	Zeitschriften-Lesesaal

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cancer Biomarkers: A Status Quo.

Scatena, Roberto

Advances in experimental medicine and biology

2015 Volume 867, Page(s) 3–8

Abstract: At present, there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows ... ...

Abstract	At present, there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring show dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarkers does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and "polluted" knowledge may have dramatic consequences for patient. A critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time can facilitate the research of new and more sensitive-specific signals of the cancer cell proliferation.
MeSH term(s)	Biomarkers, Tumor/analysis ; Humans ; Neoplasms/diagnosis
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2015
Publishing country	United States
Document type	Journal Article
ISSN	2214-8019 ; 0065-2598
ISSN (online)	2214-8019
ISSN	0065-2598
DOI	10.1007/978-94-017-7215-0_1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Remarks on Mitochondrial Myopathies

Patrizia Bottoni / Giulia Gionta / Roberto Scatena

International Journal of Molecular Sciences, Vol 24, Iss 1, p

2022 Volume 124

Abstract: Mitochondrial myopathies represent a heterogeneous group of diseases caused mainly by genetic mutations to proteins that are related to mitochondrial oxidative metabolism. Meanwhile, a similar etiopathogenetic mechanism (i.e., a deranged oxidative ... ...

Abstract	Mitochondrial myopathies represent a heterogeneous group of diseases caused mainly by genetic mutations to proteins that are related to mitochondrial oxidative metabolism. Meanwhile, a similar etiopathogenetic mechanism (i.e., a deranged oxidative phosphorylation and a dramatic reduction of ATP synthesis) reveals that the evolution of these myopathies show significant differences. However, some physiological and pathophysiological aspects of mitochondria often reveal other potential molecular mechanisms that could have a significant pathogenetic role in the clinical evolution of these disorders, such as: i. a deranged ROS production both in term of signaling and in terms of damaging molecules; ii. the severe modifications of nicotinamide adenine dinucleotide (NAD)+/NADH, pyruvate/lactate, and α-ketoglutarate (α-KG)/2- hydroxyglutarate (2-HG) ratios. A better definition of the molecular mechanisms at the basis of their pathogenesis could improve not only the clinical approach in terms of diagnosis, prognosis, and therapy of these myopathies but also deepen the knowledge of mitochondrial medicine in general.
Keywords	mitochondria ; oxidative metabolism ; electron respiratory chain ; mutations ; mitochondrial DNA ; reactive oxygen species ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
Subject code	610
Language	English
Publishing date	2022-12-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Mitochondrial Metabolism in Cancer. A Tangled Topic. Which Role for Proteomics?

Bottoni, Patrizia / Scatena, Roberto

Advances in experimental medicine and biology

2019 Volume 1158, Page(s) 1–16

Abstract: Given the role of mitochondria in modulating many cellular functions, it is not surprising that they can play a crucial role also in molecular pathophysiology of cancer. In particular, the discovery in recent decades of a link between cancer metabolic ... ...

Abstract	Given the role of mitochondria in modulating many cellular functions, it is not surprising that they can play a crucial role also in molecular pathophysiology of cancer. In particular, the discovery in recent decades of a link between cancer metabolic processes, alterations of mitochondrial DNA, oncogenes and tumor suppressors has led not only to a renaissance of interest in Warburg's pioneering work, but also to a reexamination of his original observations above all in relation to the current knowledge in cancer cell metabolism. It follows that, although mitochondrial contribution to the pathogenesis of cancer has historically tended to be neglected, it is now evident that reprogrammed mitochondria can contribute to a complex bioenergetic adjustment that sustains not only tumor formation but also its progression. Most importantly, cancer cell metabolism seems to have a role in diversified aspects related to cancer pathophysiology (i.e., aggressiveness, recurrence, metastatic dissemination). Hence, it is imperative to always consider cancer cell metabolism, its adaptability, its influences but, above all, its functional heterogeneity in a single tumor, for a really rational and valid approach towards molecular biology of cancer.
MeSH term(s)	Energy Metabolism ; Humans ; Mitochondria/metabolism ; Neoplasms/physiopathology ; Oncogenes ; Proteomics
Language	English
Publishing date	2019-08-26
Publishing country	United States
Document type	Journal Article
ISSN	2214-8019 ; 0065-2598
ISSN (online)	2214-8019
ISSN	0065-2598
DOI	10.1007/978-981-13-8367-0_1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The Tangled Mitochondrial Metabolism in Cancer: An Innovative Pharmacological Approach.

Bottoni, Patrizia / Scatena, Roberto

Current medicinal chemistry

2019 Volume 27, Issue 13, Page(s) 2106–2117

Abstract: Background: Mitochondria are remarkably gaining significant and different pathogenic roles in cancer (i.e., to sustain specific metabolism, to activate signaling pathways, to promote apoptosis resistance, to favor cancer cell dissemination, and finally ... ...

Abstract	Background: Mitochondria are remarkably gaining significant and different pathogenic roles in cancer (i.e., to sustain specific metabolism, to activate signaling pathways, to promote apoptosis resistance, to favor cancer cell dissemination, and finally to facilitate genome instability). Interestingly, all these roles seem to be linked to the fundamental activity of mitochondria, i.e. oxidative metabolism. Intriguingly, a typical modification of mitochondrial oxidative metabolism and reactive oxygen species production/ neutralization seems to have a central role in all these tangled pathogenic roles in cancer. On these bases, a careful understanding of the molecular relationships between cancer and mitochondria may represent a fundamental step to realize therapeutic approaches blocking the typical cancer progression. The main aim of this review is to stress some neglected aspects of oxidative mitochondrial metabolism of cancer cells to promote more translational research with diagnostic and therapeutic potential. Methods: We reviewed the available literature regarding clinical and experimental studies on various roles of mitochondria in cancer, with attention to the cancer cell mitochondrial metabolism. Results: Mitochondria are an important source of reactive oxygen species. Their toxic effects seem to increase in cancer cells. However, it is not clear if damage depends on ROS overproduction and/or defect in detoxification. Failure of both these processes is likely a critical component of the cancer process and is strictly related to the actual microenvironment of cancer cells. Conclusions: Mitochondria, also by ROS production, have a fundamental pathogenetic role in promoting and maintaining cancer and its spreading. To carefully understand the tangled redox state of cancer cells mitochondria represents a fundamental step to realize therapeutic approaches blocking the typical cancer progression.
MeSH term(s)	Apoptosis ; Humans ; Mitochondria ; Neoplasms ; Oxidation-Reduction ; Oxidative Stress ; Reactive Oxygen Species ; Tumor Microenvironment
Chemical Substances	Reactive Oxygen Species
Language	English
Publishing date	2019-08-07
Publishing country	United Arab Emirates
Document type	Journal Article ; Review
ZDB-ID	1319315-6
ISSN	1875-533X ; 0929-8673
ISSN (online)	1875-533X
ISSN	0929-8673
DOI	10.2174/0929867326666190823163009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4432: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation.

Scatena, Roberto

Advances in experimental medicine and biology

2012 Volume 942, Page(s) 287–308

Abstract: At the beginning of the twentieth century, Otto Warburg demonstrated that cancer cells have a peculiar metabolism. These cells preferentially utilise glycolysis for energetic and anabolic purposes, producing large quantities of lactic acid. He defined ... ...

Abstract	At the beginning of the twentieth century, Otto Warburg demonstrated that cancer cells have a peculiar metabolism. These cells preferentially utilise glycolysis for energetic and anabolic purposes, producing large quantities of lactic acid. He defined this unusual metabolism "aerobic glycolysis". At the same time, Warburg hypothesised that a disruption of mitochondrial activities played a precise pathogenic role in cancer. Because of this so-called "Warburg effect", mitochondrial physiology and cellular respiration in particular have been overlooked in pathophysiological studies of cancer. Over time, however, many studies have shown that mitochondria play a fundamental role in cell death by apoptosis or necrosis. Moreover, metabolic enzymes of the Krebs cycle have also recently been recognised as oncosuppressors. Recently, a series of studies were undertaken to re-evaluate the role of oxidative mitochondrial metabolism in cancer cell growth and progression. Some of these data indicate that modulation of mitochondrial respiration may induce an arrest of cancer cell proliferation and differentiation (pseudodifferentiation) and/or or death, suggesting that iatrogenic manipulation of some mitochondrial activities may induce anticancer effects. Moreover, studying the role of mitochondria in cancer cell dedifferentiation/differentiation processes may allow further insight into the pathophysiology and therapy of so-called cancer stem cells.
MeSH term(s)	Apoptosis ; Cell Differentiation ; DNA, Mitochondrial/genetics ; Humans ; Mitochondria/physiology ; Mutation ; Neoplasms/genetics ; Neoplasms/metabolism ; Neoplasms/pathology ; Reactive Oxygen Species/metabolism
Chemical Substances	DNA, Mitochondrial ; Reactive Oxygen Species
Language	English
Publishing date	2012
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2214-8019 ; 0065-2598
ISSN (online)	2214-8019
ISSN	0065-2598
DOI	10.1007/978-94-007-2869-1_13
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Mitochondria and drugs.

Scatena, Roberto

Advances in experimental medicine and biology

2012 Volume 942, Page(s) 329–346

Abstract: Mitochondria play a central role in the life and death of cells. They are not merely the centre for energy metabolism, but are also the headquarters for different catabolic and anabolic processes, calcium fluxes, and various signalling pathways. ... ...

Abstract	Mitochondria play a central role in the life and death of cells. They are not merely the centre for energy metabolism, but are also the headquarters for different catabolic and anabolic processes, calcium fluxes, and various signalling pathways. Mitochondria maintain homeostasis in the cell by interacting with reactive oxygen-nitrogen species and responding adequately to different stimuli. In this context, the interaction of pharmacological agents with mitochondria is an aspect of molecular biology that is too often disregarded, not only in terms of toxicology but also from a therapeutic point of view, especially considering the potential therapeutic applications related to the modulation of mitochondrial activity.At the mitochondrial level, there are several potential drug targets that can lead to toxicity, but only for few of them, a real clinical counterpart has been demonstrated. Recently, antiviral nucleoside analogues have shown mitochondrial toxicity through the inhibition of DNA polymerase-gamma. Other drugs targeted to different components of the mitochondrial channels can disrupt ion homeostasis or affect the mitochondrial permeability transition pore. Many molecules are known inhibitors of the mitochondrial electron transport chain, interfering with one or more of the complexes in the respiratory chain. Some drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), may lead to uncoupling of oxidative phosphorylation, while the mitochondrial toxicity of other drugs seems to depend on the production of free radicals, although this mechanism has yet to be defined. Besides toxicity, other drugs have been targeted to mitochondria to treat mitochondrial dysfunctions. Many drugs have been recently developed to target the mitochondria of cancer cells in order to trigger apoptosis or necrosis. The aim of this chapter is to underline the role of mitochondria in pharmacology and toxicology, stressing all the potential therapeutic approaches being due to iatrogenic modulation of the multitude of mitochondrial activities.
MeSH term(s)	Electron Transport ; Humans ; Mitochondria/drug effects ; Mitochondria/metabolism ; Oxidative Phosphorylation ; Pharmaceutical Preparations/metabolism
Chemical Substances	Pharmaceutical Preparations
Language	English
Publishing date	2012
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2214-8019 ; 0065-2598
ISSN (online)	2214-8019
ISSN	0065-2598
DOI	10.1007/978-94-007-2869-1_15
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunohistochemistry Assay Versus the Dako PD-L1 IHC 22C3 Assay in Patients With Advanced or Metastatic Triple-Negative Breast Cancer Treated With Atezolizumab in Combination With Nab-Paclitaxel

Cristian Scatena / Roberto Ravasio / Paola Raimondo / Mario Giuliano

Farmeconomia: Health Economics and Therapeutic Pathways, Vol 22, Iss

2021 Volume 1

Abstract: OBJECTIVE: To estimate the budget impact determined by the adoption of two different diagnostic strategies, SP142 assay or 22C3 assay, in the identification (in terms of PD-L1 status) of patients with mTNBC eligible for treatment with atezolizumab in ... ...

Abstract	OBJECTIVE: To estimate the budget impact determined by the adoption of two different diagnostic strategies, SP142 assay or 22C3 assay, in the identification (in terms of PD-L1 status) of patients with mTNBC eligible for treatment with atezolizumab in combination with nab-paclitaxel. METHODS: The budget impact analysis (BIA) was conducted using a budget impact model (BIM) considering the Italian National Health Service’s (iNHS) perspective. The analysis assessed only the direct medical cost (tissue biopsy, PD-L1 assay, specialist visit, pharmacological treatment with atezolizumab in combination with nab-paclitaxel) of patients with PD-L1 positive mTNBC, and management of the adverse events associated with the pharmacological treatment administered. The BIM also considered the clinical benefits (progression free survival, PFS) resulting from the drug therapy administered on the basis of the results of the post-hoc analysis of the IMpassion130 clinical trial. The BIA was conducted over a 1-year time horizon. The median cost per patient in the progression-free state was also calculated. The costs were calculated using the net ex-factory prices (cancer drugs) and regional or national tariffs (tissue biopsy, PD-L1 assay, specialist visit and adverse events management). A sensitivity analysis was conducted to evaluate the base case result. RESULTS: The SP142 assay diagnostic pathway would result in a reduction of the iNHS expenditure of approximately 5.6 million euros (-12%). Almost all of the reduction in iNHS expenditure would be determined by the lower number of patients treated (SP142: 689 patients vs 22C3: 786 patients) with immunotherapy (-€ 5,530,871). Compared with 22C3 assay, the SP142 assay shows a cost per PFS month reduction of € 736 (€ 7,010 vs € 7,746). CONCLUSIONS: The use of the SP142 assay proved to be cost-effective compared to the 22C3 assay; the SP142 assay can support the choice of the most appropriate cancer drug, maximizing the effectiveness and minimizing the waste of healthcare resources.
Keywords	ventana pd-l1 sp142 assay ; triple-negative breast cancer ; atezolizumab ; budget impact ; italian nhs ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2021-07-01T00:00:00Z
Publisher	SEEd Medical Publishers
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED